The Most N-Terminal Region of THSD7A Is the Predominant Target for Autoimmunity in THSD7A-Associated Membranous Nephropathy

• Published in: Journal of the American Society of Nephrology Vol. 29; no. 5; pp. 1536 - 1548
• Main Authors: Seifert, Larissa, Hoxha, Elion, Eichhoff, Anna M, Zahner, Gunther, Dehde, Silke, Reinhard, Linda, Koch-Nolte, Friedrich, Stahl, Rolf A K, Tomas, Nicola M
• Format: Journal Article
• Language: English
• Published: United States American Society of Nephrology 01.05.2018
• Subjects: Aged; Animals; Antigens, Surface - genetics; Antigens, Surface - immunology; Autoantibodies - blood; Clinical Research; Computer Simulation; DNA, Complementary - immunology; Epitopes - immunology; Female; Glomerulonephritis, Membranous - complications; Glomerulonephritis, Membranous - immunology; HEK293 Cells; Humans; Male; Membrane Proteins - genetics; Membrane Proteins - immunology; Mice; Middle Aged; Protein Domains - immunology; Proteinuria - etiology; Rabbits; Thrombospondins - immunology; Thrombospondins - metabolism; membranous nephropathy; clinical immunology; glomerular disease
• ISSN: 1046-6673; 1533-3450
• DOI: 10.1681/ASN.2017070805

Thrombospondin type 1 domain-containing 7A (THSD7A) has been identified as a pathogenic autoantigen in membranous nephropathy (MN). However, the THSD7A epitopes targeted by patient autoantibodies are unknown. We performed an analysis of the THSD7A multidomain structure, expressed the folded domains in HEK293 cells, and tested for domain reactivity with 31 serum samples from patients with THSD7A-associated MN using Western and native blotting. Immunogenicity of the antigen domains was further investigated by cDNA immunization of rabbits and mice. We characterized the extracellular topology of THSD7A as a tandem string of 21 thrombospondin type 1 domains. Overall, 28 serum samples (90%) recognized multiple epitope domains along the molecule. Detailed epitope mapping revealed that the complex consisting of the first and second N-terminal domains (amino acids 48-192) was recognized by 27 of 31 patient serum samples (87%). Serum recognizing one or two epitope domains showed lower anti-THSD7A antibody levels than serum recognizing three or more epitope domains. During follow-up, a loss of epitope recognition was observed in seven of 16 patients, and it was accompanied by decreasing antibody levels and remission of proteinuria. In four of 16 patients, epitope recognition patterns changed during follow-up. Notably, immunization experiments in rabbits and mice revealed that induced antibodies, like patient autoantibodies, preferentially bound to the most N-terminal domains of THSD7A. Our data show that the immune response in THSD7A-associated MN is polyreactive and that autoantibodies predominantly target the most N-terminal part of THSD7A.